Moving toward a precision medicine approach in metastatic castration-resistant prostate cancer

Affiliations

Comment

Rahul Aggarwal. Lancet Oncol. 2017 Nov.

. 2017 Nov;18(11):1436-1437.

doi: 10.1016/S1470-2045(17)30718-0. Epub 2017 Oct 9.

¹ Department of Medicine, University of California, San Francisco, CA 94122, USA.

No abstract available

Comment on

Custirsen (OGX-011) combined with cabazitaxel and prednisone versus cabazitaxel and prednisone alone in patients with metastatic castration-resistant prostate cancer previously treated with docetaxel (AFFINITY): a randomised, open-label, international, phase 3 trial.
Beer TM, Hotte SJ, Saad F, Alekseev B, Matveev V, Fléchon A, Gravis G, Joly F, Chi KN, Malik Z, Blumenstein B, Stewart PS, Jacobs CA, Fizazi K. Beer TM, et al. Lancet Oncol. 2017 Nov;18(11):1532-1542. doi: 10.1016/S1470-2045(17)30605-8. Epub 2017 Oct 9. Lancet Oncol. 2017. PMID: 29033099 Clinical Trial.